It is still unclear whether cardiovascular events affect the progression to end-stage renal disease among type 2 diabetes patients. Researchers aimed to explore this further in a recent study, using data...
While older adults with type 2 diabetes often have greater areal bone mineral density compared with those without diabetes, they have a higher risk for fracture. A recent study investigated structural...
In a recent study, researchers investigated whether adding ertugliflozin to metformin and sitagliptin improved glycemic control in patients with inadequately controlled type 2 diabetes.
In a recent study, researchers investigated the association between diabetes and dementia, as well as whether having diabetes influenced the likelihood of patients receiving appropriate dementia treatment....
In a recent study, researchers evaluated the respective abilities of the plasma and urine kynurenine:tryptophan ratios to predict the risk of incident type 2 diabetes among individuals with coronary artery...
Emerging data has suggested that canagliflozin provides more benefits to patients with type 2 diabetes vs sitagliptin. In a recent study, researchers compared the effects of both treatments on glycemic...
Previous studies have shown that empagliflozin can significantly lower the risk of cardiovascular death vs placebo among individuals with type 2 diabetes and cardiovascular disease. In a recent study,...
In a recent study, researchers assessed the safety and efficacy of dapagliflozin as an add-on to insulin in patients with poorly controlled type 1 diabetes.
